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Abstract 
This systematic review evaluates the clinical evidence for the addition of herbal medicines (HMs) to 
FOLFOX 4 for advanced colorectal cancer (ACRC) in terms of tumor response rate (tRR), survival, quality 
of life and reduction in adverse events (AEs). Seven electronic databases were searched for randomized 
controlled trials (RCTs) of FOLFOX4 combined with HMs compared to FOLFOX4 alone. Outcome data for 
13 randomized controlled trials were analysed using Review Manager 5.1. Risk of bias for objective 
outcomes including tumor response and survival was judged as low. Publication bias was not evident. Meta-
analyses found the addition of HMs improved tRR (RR 1.25, 95%CI 1.06-1.47, I²=0%), one year survival 
(RR 1.51, 95%CI 1.19-1.90, I²=0%), and quality of life in terms of Karnofsky Performance Status (KPS) 
gained (RR 1.84, 95%CI 1.54-2.19, I²=0%); alleviated grade 3 and 4 chemotherapy-related AEs for 
neutropenia (RR 0.33, 95%CI 0.18-0.60, I²=0%), nausea and vomiting (RR 0.34, 95%CI 0.17-0.67, I²=0%) 
and neurotoxicity (RR 0.39, 95%CI 0.15-1.00, I²=0%), compared to FOLFOX4 alone. The most frequently 
used herbs were Astragalus membranaceus, Panax ginseng, Atractylodes macrocephala, Poria cocos, Coix 
lachryma-jobi and Sophora flavescens. In experimental studies, each of these herbs has shown actions that 
could have contributed to improved tumor response. 
 
Key words (6): colorectal cancer, FOLFOX, herbal medicine, tumor response, quality of life, meta-
analysis 
 
Abbreviations 
ACRC: Advanced Colorectal Cancer  
AEs: Adverse Events  
BW: Body Weight 
CAM: Complementary and Alternative Medicine 
CNKI: China Academic Journals 
CQVIP: Chinese Science and Technology Journals  
CR: Complete Remission 
CRC: Colorectal Cancer 
FOLFOX: 5-Fluorouracil (5-FU) plus Leucovorin (LV) combined with Oxaliplatin 
HMs: Herbal Medicines  
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KPS: Karnofsky Performance Status 
MD: Mean Difference 
NCI-CTC: National Cancer Institute Common Toxicity Criteria 
NK: Natural Killer 
OS: Overall Survival  
PD: Progressive Disease 
PR: Partial Remission 
QoL: Quality of Life 
RCT: Randomized Controlled Trial 
RD: Risk Difference 
RECIST: Response Evaluation Criteria in Solid Tumors   
RR: Risk Ratio 
SD: Stable Disease 
TNM: Tumor Node Metastasis  
tRR: Tumor Response Rate 
TTP: Time to Progression  
WHO: World Health Organisation 
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Introduction 
Complementary and alternative medicine (CAM) use is common in cancer patients and more than 
50% of patients use one or more type of CAM after the diagnosis (Vapiwala et al., 2006), mostly with 
the aim of improving health and well-being, boosting the immune system and controlling symptoms 
associated with the disease and treatments (Mansky and Wallerstedt, 2006). In a review of studies of 
CAM usage by colorectal cancer (CRC) patients in Western countries, Sewitch et al 2010 reported up 
to 75% prevalence of CAM use and herbal medicines (HM) were used by 48.7% of CRC patients in a 
European survey (Sewitch and Rajput, 2010). An estimated 1.5 billion people use Chinese HM 
worldwide (Dobos et al., 2005). In cancer therapy, Chinese HM has been reported to alleviate adverse 
events (AEs) induced by conventional cancer therapy and improve patient’s quality of life (QoL) 
(Molassiotis et al., 2009), enhance cellular immunity of cancer patients receiving 
chemotherapy/radiotherapy (Zhuang et al., 2009), reduce cancer pain (Xu et al., 2007), relieve cancer 
related fatigue (Jeong et al., 2010), and improve anorexia and cachexia (Lee and Lee, 2010). Meta-
analyses of clinical studies have demonstrated the addition of Chinese HMs to conventional therapy 
appears to improve tumour response and prolong survival in liver cancer (Shu et al., 2005) and in lung 
cancer (McCulloch et al., 2006) 
Experimental studies have demonstrated that bio-active components in a number of single HMs and 
multi-herb formulae possess anti-cancer potential. In separate reviews, researchers explored the anti-
cancer mechanisms of Chinese HMs and summarized these as multi-action and multi-targeted (Han 
and Li, 2009; Parekh et al., 2009). The actions of HMs include anti-proliferative activity in cancer 
cells and induction of tumor cell apoptosis (Auyeung and Ko, 2010; Guo et al., 2013; Nguyen et al., 
2013; Tin et al., 2007; Wang et al., 2009a); tumour angiogenesis suppression (Jeong et al., 2011; Law 
et al., 2012; Wang et al., 2009b); telomerase activity inhibition (Yu et al., 2006); immune function 
regulation (Gong, 2010); reversal of multiple drug resistance (Huang et al., 2011; Wang et al., 2007; 
Zhang et al., 2011); enhancing the cytotoxicity of the chemotherapy regimen (Cao et al., 2012; Tin et 
al., 2007); and management of chemotherapy side effects (Chen et al. 2009; Zhu et al 2007).  
The FOLFOX regimen refers to 5-Fluorouracil (5-FU) plus Leucovorin (LV) combined with 
Oxaliplatin. It is a standard first line combination chemotherapy setting for advanced CRC (ACRC) 
(Lee and Chu, 2007; Prescrire Editorial Staff, 2010). A number of modalities of FOLFOX regimens, 
which consist of varying doses and schedules of 5-FU, LV and Oxaliplatin, have been studied in 
palliative settings. Of these, FOLFOX4 has been the most widely investigated (Waddell and 
Solimando, 2005). FOLFOX4 comprises a 2-hour infusion of LV (200 mg/ m²/d), followed by a 5-FU 
bolus (400 mg/ m²/d) and a 22-hour infusion (600 mg/ m²/d) for 2 consecutive days every 2 weeks, 
together with Oxaliplatin 85 mg/m² as a 2-hour infusion on day 1. It is used in conjunction with anti-
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nausea medications. The regimen is repeated every 14 days until disease progression or unacceptable 
toxicities force cessation (De Gramont et al., 2000).  
FOLFOX4 has good evidence of efficacy for ACRC and is widely used but there are still AEs and 
these remain a major reason for discontinuation (Raftery and Goldberg, 2010). Consequently, 
clinicians may add HMs to the chemotherapy with the aim of reducing AEs and improving clinical 
outcomes (Saif et al., 2010). Systematic reviews of Chinese HMs in CRC treatment found that 
Chinese HM as an adjuvant treatment during chemotherapy for CRC prolonged 1 year and 3 year 
survival time, improved QoL, and reduced the incidence of chemotherapy-related AEs such as 
vomiting and nausea, diarrhoea, and leukopenia (Liu and Zhu, 2009; Wu et al., 2005; Zhong et al., 
2012). However, these studies included various stages of CRC and various chemotherapy regimens. 
One systematic review that focussed on randomized or quasi-randomized controlled trials of Chinese 
HMs for ACRC using a variety of chemotherapy regimens found the addition of the HMs reduced 
mortality rate, improved 1 year and 3 year survival rate and QoL but the addition of the HMs did not 
benefit tumor response rate (tRR) (Guo et al., 2012).  
This reviews focuses on HMs as adjuvants to FOLFOX4 in the treatment of ACRC. It includes 
randomized controlled trials (RCTs) published in medical journals and aims to determine which, if 
any, HMs demonstrate evidence of efficacy and safety in the treatment of ACRC and/or the 
management of the side effects of FOLFOX4 and to identify which HMs could have beneficial effects 
in ACRC. 
Method 
Searches were conducted of PubMed, Cochrane CENTRAL, CINAHL, Science Direct, PsycINFO, 
China Academic Journals (CNKI) and Chinese Science and Technology Journals (CQVIP) from their 
inceptions to December 2012. Three groups of search terms were used: 1. Disorder: colorectal cancer 
and related terms; 2. Intervention: herbal medicine, complementary medicine, Chinese medicine and 
related terms; and 3. Study type: controlled trial, randomised and related terms, with modifications 
according to the individual database. Full lists of search terms are available on request. Results were 
downloaded to Endnote libraries and combined. Reference lists in review articles and clinical studies 
were also searched. 
Included studies were RCTs that employed FOLFOX4 combined with an HM intervention in the test 
arm and FOLFOX4 in the control arm, regardless of blinding with no restrictions on language or 
publication year. Participants were aged 18 to 80 years and had been pathologically diagnosed with 
ACRC that was either metastatic or regionally advanced, with Tumor Node Metastasis (TNM) stage 
IV, so curative surgical resection was unlikely to be carried out. Test interventions were HMs used 
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singly or in combination, in any form including extracts and by any administration route. Only studies 
that provided data on at least one CRC-related primary or secondary outcome measure were included. 
Outcome measures could include tRR, survival, QoL, immune function and/or AEs.  
Data extraction and Risk of Bias assessments were conducted by two reviewers independently (MC & 
IZ) with mediation by AZ or BM. Data were extracted using pre-designed data collection forms. The 
validity of the outcomes of the included studies was assessed using the Cochrane Risk of Bias 
assessment method which includes the following categories of bias: selection bias, performance bias, 
detection bias, attrition bias, and reporting bias. The approach was according to the Cochrane 
Handbook version 5.1.0 (Higgins et al., 2011). Each domain was labelled ‘low risk’ or ‘high risk’ or 
‘unclear risk’, with the last category indicating that there was insufficient information to judge the 
potential for bias. 
Review Manager (RevMan) 5.1 was used for meta-analysis. Methods were based on Cochrane 
Handbook 5.1.0. Risk Ratio (RR) or Mean Difference (MD) with 95% confidence intervals (95% CI) 
using fixed or random-effect models depending upon heterogeneity were used. Risk Difference (RD) 
was calculated and presented as the percentage difference between the RRs of the test and control 
groups. The proportion of heterogeneity was measured using I². It was defined as substantial 
heterogeneity if I² was more than 50%. In such cases sensitivity tests were done. When the same 
outcome was reported by more than 10 studies, publication bias was assessed using a funnel plot 
(Higgins et al., 2011).  
Results 
Database searches located 1,927 potentially relevant citations and 37 studies were identified by 
checking reference lists and print journals. Following screening, 68 studies were considered. These 
included nine studies that compared HM with placebo, no treatment, or chemotherapy and 58 that 
compared the combination of HM plus a non-FOLFOX4 chemotherapy regimen with the 
chemotherapy alone. Thirteen studies (Ding et al., 2010; Fang and Li, 2008; Li et al., 2007b; Li et al., 
2007c; Qiu, 2011; Wu G et al., 2010; Xu and Wang, 2010; Yang, 2008; Zeng et al., 2009; Zeng et al., 
2008; Zhang et al., 2008; Zhang et al., 2010a; Zhang et al., 2010b) that investigated a combination of 
HM plus FOLFOX4 versus FOLFOX4 for ACRC were included in this review (Fig 1).  
The 13 studies enrolled 940 assessable in-patient participants with 486 participants in the test groups 
and 454 participants in the control groups. All studies were conducted in China and published in 
Chinese medical journals from 2007 to 2011. Participant characteristics, interventions and outcome 
measurements are summarized in Table 1.  
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Twelve different test interventions were used. Seven studies employed commercially available HM 
extracts. Kang’ai Injection was used in two studies. Compound Kushen injection, Ginsenoside Rg3 
capsules, Aidi injection, Guben Xiaoliu Capsule and Javanica oil injection were each used in one 
study. Six studies used multi-herbal decoctions. In total, 58 different herbs and/or their extracts were 
used, with the six most frequent being:  
Huang qi Astragalus membranaceus (Fisch.) Bge. root (7 studies) (Li et al., 2007b; Li et al., 2007c; 
Qiu, 2011; Yang, 2008; Zeng et al., 2008; Zhang et al., 2008; Zhang et al., 2010b);  
Yi yi ren Coix lachryma-jobi L. seed (6 studies) (Li et al., 2007c; Wu et al., 2010; Xu and Wang, 
2010; Zeng et al., 2008; Zhang et al., 2008; Zhang et al., 2010a);  
Ren shen Panax ginseng C.A.Mey. root (5 studies) (Li et al., 2007b; Qiu, 2011; Yang, 2008; Zeng et 
al., 2009; Zhang et al., 2010a);  
Ku shen Sophora flavescens Ait. root (5 studies) (Ding et al., 2010; Qiu, 2011; Yang, 2008; Zeng et 
al., 2008; Zhang et al., 2008);  
Bai zhu Atractylodes macrocephala Koidz. root (5 studies) (Li et al., 2007c; Xu and Wang, 2010; 
Zeng et al., 2008; Zhang et al., 2008; Zhang et al., 2010b); and  
Fu ling Poria cocos (Schw) Wolf sclerotium (4 studies) (Li et al., 2007c; Wu et al., 2010; Xu and 
Wang, 2010; Zhang et al., 2008). 
Methodological assessment 
All studies claimed to be randomized. Five studies (38.4%) stated a proper method of generation of 
randomization sequence, so the risk of bias was judged as ‘low’ in these studies (Ding et al., 2010; 
Fang and Li, 2008; Li et al., 2007c; Wu et al., 2010; Zhang et al., 2010a). The other eight studies did 
not describe the randomization method and were judged as ‘unclear’. None of the studies described 
the procedure of allocation concealment. Therefore, an ‘unclear’ judgement was made (Table 1).  
A placebo group was not used in any of the studies and none reported a method of blinding. There is 
generally no blinding in oncology trials (Hind D et al., 2008), so we expect that all trials were open to 
participants and personnel. Thus, there was possible performance bias and detection bias for 
subjective outcomes such as QoL and AEs. Therefore a ‘high’ risk of bias was judged for subjective 
outcomes. Radiologists and laboratory pathologists measured the objective outcomes, such as tumor 
response and laboratory tests. Outcome data on survival rate and time to progression was obtained 
from medical records. These kinds of data were unlikely to have been influenced by lack of blinding, 
so we judged ‘low risk’ of detection bias for these outcomes. Three studies reported the numbers of 
participants who dropped out during the trial or were lost to follow-up (Ding et al., 2010; Li et al., 
2007c; Zhang et al., 2010b) but no reasons were given and these missing data were not treated as 
‘intent to treat’. So, these were judged as ‘high risk’ of attrition bias. Studies that had the same 
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numbers of participants at the inception as at the outcome reports were judged as ‘low risk’ of attrition 
bias. None of the studies had published study protocols. When the study objectives and outcome 
measures were stated in the study method section and when all outcomes were reported in the results 
section, the study was judged as ‘low risk’ of reporting bias (Table 1). 
Twelve studies reported on tRR so a Funnel Plot was used to assess publication bias (Fig. 2). The 
symmetry of the Funnel Plot suggests the risk of publication bias was low for these studies. 
Meta-analysis results 
Meta-analyses were performed for each of the following outcomes. The numerical data are presented 
in Table 2.  
1. Tumor response rate (tRR) 
 
Twelve studies reported tRR. Ten evaluated tRR using the WHO solid tumor response criteria (Miller 
et al., 1981) as follows: complete remission (CR), partial remission (PR), stable disease (SD), and 
progressive disease (PD). The other two studies (Qiu, 2011; Zhang et al., 2010b) used the RECIST 
criteria, which use similar categories (Park t al., 2003), so data could be pooled for all studies. CR 
plus PR was defined as ‘clinically effective’ so these data were included in meta-analyses. When the 
Risk Ratio (RR) is more than 1 (IV model, Fixed, 95% CI) it favours the test group. Positive 
outcomes favour test groups.  
The tRR ranged from 30% to 54.1% for the test groups and from 20% to 46.6% for the control groups 
in the 12 studies (880 participants)(Fang and Li, 2008; Li et al., 2007b; Li et al., 2007c; Qiu, 2011; 
Wu G et al., 2010; Xu and Wang, 2010; Yang, 2008; Zeng et al., 2009; Zeng et al., 2008; Zhang et al., 
2008; Zhang et al., 2010a; Zhang et al., 2010b). There was a significant improvement in tRR for HMs 
plus FOLFOX4 (test groups) compared to FOLFOX4 alone (Table 2). The pooled tRR in the test 
groups was elevated to 44.1% (RD 9.2%). For the two studies of Kang'ai Injection, the RD was 3.0% 
but there was no significant difference between groups. The total numbers of complete remissions 
(CRs) in the test and control groups were 19 and 8 patients respectively but this difference was not 
significant (RD 2.8%). The tRR data included 234 (24.9%) participants who were previously treated 
with chemotherapy for ACRC but separate results were reported for only 126 of these. Previously 
treated ACRC patients have been found to be less responsive to current first-line settings of 
chemotherapy (Giantonio et al., 2007). When the subgroups of previously treated (2 studies) and 
previously untreated (3 studies) patients were analysed, the RD of the pooled tRR was 8.7% in each 
group but there was no significant difference between test and control groups (Table 2).  
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2. Overall survival (OS) and time to progression (TTP) 
Time to event data for OS was treated as dichotomous data with the number of surviving participants 
in each treatment group at one year as the event number entry and the total number of participants in 
each group as the total number entry (Higgins et al., 2011). Three studies reported one year OS. There 
was a significant difference in favour of the test groups (RD 20.2%) (Table 2). No long-term (two 
years or more) OS data were reported. 
Median OS and median TTP were each reported in three studies. Median OS was 12.5 months for the 
test group versus 10.8 months for the control group in one study (Li et al., 2007b); 13.6 months (test) 
versus 10.2 (control) in another study (Zhang et al., 2010b); and 19.8 months (test) versus 18.6 
(control) in Ding et al (2010). Median TTP was 8.1 months (test) versus 6.9 months (control) in 
Zhang et al (2010b), 9.2 (test) versus 8.7 months (control) in Ding et al (2010), and 16.5 months (test) 
versus 10.2 months (control) in Xu et al (2010). Meta-analysis was not feasible. 
 
3. Quality of life (QoL) and body weight (BW)  
Ten studies used Karnofsky Performance Status (KPS) to measure QoL changes before and after 
treatment (Li et al., 2007b; Li et al., 2007c; Qiu, 2011; Wu G et al., 2010; Xu and Wang, 2010; Zeng 
et al., 2009; Zeng et al., 2008; Zhang et al., 2008; Zhang et al., 2010a; Zhang et al., 2010b). KPS is a 
single dimension scale that provides a global measurement of patient physical function. Its reliability 
and validity have been investigated and verified (Granda-Cameron C et al., 2008). Nine studies 
defined a KPS score gain of ≥10 points as ‘improved’; a decline of ≥10 points as ‘worse’; and 
changes of less than 10 points as ‘stable’. Three studies (Yang, 2008; Zeng et al., 2009; Zhang et al., 
2010b) included body weight (BW) measurement. BW gain ≥1.0 kg was defined as ‘improved’ and 
weight loss of ≥1.0 kg was defined as ‘worse’. Changes in the range between ‘improved’ and ‘worse’ 
were defined as ‘stable’.  
Clinical effectiveness was defined as ‘improved’ for KPS and as ‘improved’ for BW. To minimize 
bias resulting from small changes in scores, the meta-analyses only included patients who recorded a 
KPS score that was 10 or more points higher after the intervention compared to prior to the 
intervention and patients who had gained 1 kg or more. Patients who achieved a stable KPS score 
and/or stable BW after the intervention were excluded from the analyses.  
The KPS improvement was significantly greater in the test groups based on 9 studies (RD 28.8%) 
(Table 2). In Wu et al (2010), KPS was presented as mean plus standard deviation (SD). There was no 
statistically significant difference before and after the treatment in the test group (MD 0.44, 95% CI -
3.94 to 4.82, p=0.84) but there was a significant decline after treatment in the control group (MD 
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13.40, 95% CI 7.22 to 19.58, p< 0.0001), so the mean KPS after treatment was significantly higher in 
the test group, indicating a relative improvement in the test group (Table 2).  
Yang (2008) reported Su Ying’s QoL Questionnaire which comprised 12 items which are scored 5-1 
according to increase in severity, so the more severe the symptoms the lower the score. In the test 
group, the total score was not significantly different before and after the treatment (MD –1.57, 95% 
CI -3.44 to 0.30, p=0.10) but it significantly decreased in the control group after treatment (MD 2.70, 
95% CI 1.34 to 4.06, p<0.0001). The between-groups scores after treatment were significantly 
different in favor of the test group (Table 2). There was a significant difference in body weight 
improvement in favour of the test group based on three studies (RD 18.9%) (Table 2). 
 
4. Alleviation of adverse events associated with chemotherapy 
 
All 13 studies reported that the HMs alleviated chemotherapy toxicity. The criteria for grading acute 
and subacute toxicity recommended by WHO (Miller et al., 1981) were used in ten studies and three 
studies (Qiu, 2011; Yang, 2008; Zhang et al., 2010a) used the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) (National Cancer Institute, 1999). These systems use similar grading 
criteria so we followed Hind (2008) and pooled data where possible (Hind D et al., 2008). Zhang et al 
reported events as gastrointestinal reactions or myelosuppression (Zhang et al., 2008), and Zeng et al 
reported toxicity events as totals (all grades) (Zeng et al., 2009). Therefore, these two studies were not 
included in the meta-analysis.  
Most of the AEs were mild (grades 1-2). The three most commonly reported AEs were nausea and 
vomiting, neutropenia, and neurotoxicity. The meta-analyses included toxic events at grades 3 and 4 
only (i.e. severe toxicity) (Table 2). The pooled grade 3 and 4 events for neutropenia (n=10, RD 
8.7%), nausea and vomiting (n=9, RD 9.5%), and neurotoxicity (n=7, RD 3.8%) were significantly 
fewer in the test groups. For the Kang'ai Injection sub-group (n=2), significant reductions were found 
for neutropenia (RD 17.8%) and nausea and vomiting events (RD 15.8%). No significant difference 
between groups was found for the pooled grade 3 and 4 events for: diarrhoea (5 studies, RD 2.4%), 
anaemia (3 studies, RD 2.9%), stomatitis (2 studies, RD 2.3%), thrombocytopenia (1 study), or 
constipation (1 study). Adverse events specific to the HMs were not reported in any of the 13 studies.  
5. Effect on immune function 
Four studies reported effects on immune function, in terms of the percentage of T-lymphocyte subsets 
and Natural Killer (NK) cell activity in serum. One study reported benefits for T-cells and NK cells 
but data were as difference scores, so these could not be included in pooling (Zeng et al., 2009). There 
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was a significant improvement in the pooled data for CD3+ cells (Wu G et al., 2010), and Ratio 
CD4+/CD8+ cells (Ding et al., 2010; Zhang et al., 2010a) (Table 2). For CD4+, CD8+ cells and NK 
cells, there were benefits reported in some studies but the pooled results were too heterogeneous to be 
meaningful.  
Discussion 
All thirteen studies included in this review were published after 2007 and all employed FOLFOX4 as 
a single regimen. Since this is currently the most commonly used first-line chemotherapy regimen for 
ACRC, the results of this review are of direct clinical relevance.  
Internationally recognized measurement systems were used in all included studies, including the TNM 
staging system, WHO criteria for solid tumor response and grading of acute and subacute toxicity, and 
the KPS scoring system. Participants’ age was in the range 48-60 in nine studies and one study 
enrolled participants whose mean age was 72.7 years (Li et al., 2007c). From an international 
perspective, the majority of the cohort was younger than the general population of CRC patients 
whose median age is over 70. A tendency for trial participants to be younger than the average CRC 
patient has been found in other ACRC trials but younger patients did not appear to respond better or 
experience less toxicity than older patients (Hind D et al., 2008), so this difference was judged as not 
likely to affect the generalizability of results. Overall, the heterogeneity of meta-analyses was low for 
the clinical outcome measures.  
The pooled data indicate the addition of the HMs significantly improved tRR when compared to 
FOLFOX4 alone (Table 2). In the sub-group analysis of tRR for previously treated and untreated 
ACRC participants the results showed a similar benefit for the HM in both groups (RD 8.7% in each) 
but this did not reach significance (Table 2). It is possible that the small number of participants in 
these sub-groups meant there was insufficient statistical power to detect a difference. The additional 
HM intervention improved CR (RD 2.8%) but it was not statistically significant. It is notable that 
FOLFOX4 itself has not yielded high CRs in ACRC (Cassidy et al., 2008; De Gramont et al., 2000; 
Goldberg et al., 2004; Goldberg et al., 2006). Overall, these results suggested that the HMs conferred 
an additional benefit to tRR when combined with FOLFOX4 for ACRC. But these results need to be 
verified by a large scale clinical trial.  
The review by Zhong et al (2012) included 20 studies that used a number of chemotherapy regimens 
for a range of CRC stages including two studies that used FOLFOX 4. These two studies were not 
included in the present meta-analysis since they did not use FOLFOX 4 alone for ACRC, so there is 
no overlap between these two reviews. Zhong et al (2012) reported benefits for tRR, survival, KPS, 
immune response and chemotherapy AEs. In contrast, the review of 20 RCTs for ACRC by Guo et al 
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(2012) found HM did not benefit tRR. Six of the studies in the present review were also included in 
Guo et al (2012). The likely reason for the different result is Guo et al (2012) analyzed tRR separately 
for each study. Since each study was small, there was insufficient statistical power to detect an effect. 
In the present review, the focus on a single chemotherapeutic intervention enabled more meaningful 
meta-analyses, as did the separate analyses of tRR for previously treated and untreated ACRC 
participants. 
One year-OS was greater in the HM plus FOLFOX4 groups compared to FOLFOX4 alone (Table 2). 
Median OS in the FOLFOX4 plus HM group ranged from 12.5 to 19.8 months (Ding et al., 2010; Li 
et al., 2007b; Zhang et al., 2010b) and the median TTP ranged from 8.1 to 16.5 months (Ding et al., 
2010; Xu and Wang, 2010; Zhang et al., 2010b). So the addition of the HM appeared to modestly 
improve both median OS and TTP but meta-analyses were not feasible.  
Other outcomes 
Participants in the test groups were more likely to show a KPS improvement than in the control 
groups (RD 28.8%). For chemotherapy-related AEs, significant reductions were found in the test 
groups for grade 3 and 4 neutropenia (T: 3.9% vs C: 12.6%), nausea and vomiting (T: 3.0% vs C: 
12.5%) and neurotoxicity (T: 2.2% vs C: 6.0%) (Table 2). These findings were generally consistent 
with earlier reviews of HM adjuvant to chemotherapy for CRC (Liu and Zhu, 2009; Wu et al., 2005; 
Zhong et al., 2012).  
The results for T-lymphocyte subsets suggest that some HMs may have immune enhancing effects but 
these data were only available for a few studies and there was substantial heterogeneity in some of the 
meta-analyses (Table 2). It is notable that the following HMs that were used in these studies, 
Astragalus membranaceous, Panax ginseng, Atractylodes macrocephala, Poria cocos and Coix 
lachryma-jobi, have been reported to have immunomodulatory effects (Gong, 2010; Yang et al., 2002; 
Yang et al., 2011).  
Comparison with other studies of FOLFOX4 
The improvement in tRR of 20.0% to 46.6 % (average 34.9%) for the control groups in 12 studies was 
consistent with the results of a review by Lu et al (2010) that pooled 27 clinical studies of FOLFOX4 
for ACRC conducted in China (879 participants), none of which involved a comparison with HM (Lu 
et al., 2010). The review by Lu et al found the following tRRs: total 26.10-57.14% (27 studies); 
previously untreated patients 30.8-65.0% (12 studies); and previously treated patients 16.6-47.6% (12 
studies). In this review, the pooled tRRs of 34.9% for all control group participants, 42.4 % for 
previously untreated participants, and 21.0% for previously treated participants all fell within these 
ranges, so the results for the control groups in this review are broadly consistent with non-HM studies 
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conducted in China on FOLFOX4. In the control groups in this review, the median OS was 10.2-18.6 
months and the TTP was 6.9-10.2 months, which were similar to the ranges found in the review by Lu 
et al (OS 9.0-17.7 months, TTP 5.47-9.00 months) (Lu et al., 2010).  
We noticed the average tRR (34.9%) in the control groups in this review and in the review of Chinese 
FOLFOX4 studies (Lu et al., 2010) were relatively low compared to large international trials (Cassidy 
et al., 2008; De Gramont et al., 2000; Goldberg et al., 2004; Goldberg et al., 2006) in which the tRRs 
were in the range 45.0-58.5%. These international trials only included previously untreated ACRC, 
whereas in this review the trial participants were both previously treated and untreated ACRC 
participants and there were no second line treatments in the Chinese trials. Both these factors could 
adversely affect the outcomes for tRR (De Gramont et al., 2000; Giantonio et al., 2007).  
In the included studies, the most common FOLFOX4-related grade 3 and 4 AEs were neutropenia, 
nausea and vomiting, diarrhoea, and neurotoxicity, which are the same as in the international studies 
(Cassidy et al., 2008; De Gramont et al., 2000; Goldberg et al., 2004; Goldberg et al., 2006). 
However, the incidence rates for grade 3-4 neutropenia, neurotoxicity and diarrhoea in the pooled 
control group data were less than in the international studies. A likely reason for this difference is the 
relatively short duration of treatment in the studies in this review, since neutropenia and neurotoxicity 
tend to become more severe the longer the chemotherapy continues (Boisdron-Celle et al., 2002; De 
Gramont et al., 2000). The grade 3-4 nausea and vomiting rate was comparable to the international 
studies. This may due to the preventive use of anti-emetic drugs and dose modification in FOLFOX4 
protocols which enable control of the severity of nausea and vomiting even with longer treatment.  
 
Limitations to this systematic review 
 
In interpreting the findings of this systematic review a number of factors need to be considered 
including methodological issues, trial duration, the nature and size of study samples, and variation in 
the HMs used. All studies claimed to be randomized but only five stated an appropriate method of 
sequence generation and none provided information on allocation concealment procedures, so there 
was potential for selection bias. Lack of blinding increases the risk of bias for subjective outcomes 
such as KPS and AEs such as nausea, so the results for these outcomes should be considered less 
reliable than for more objective measures such as tRR and OS. Three studies did not report reasons 
for dropouts or loss to follow-up. Methodological issues of these types have been found in trials of 
both conventional medicine and HM conducted in China (Wu et al., 2009). Clinical trial reporting 
needs to be clear, complete and transparent (Moher et al., 2010), so there is a pressing need for 
improvements in the conduct of clinical trials in China and for proper reporting of methods and results 
in Chinese journals. 
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Most the studies were relatively small and small trials appear to overestimate true effects (Higgins et 
al., 2011). Some trials appear to have included both previously treated and untreated participants 
without reporting separate results for these two groups who could be expected to show differential 
responses to interventions. Other issues are quality control of the medicines prepared by the 
investigators’ hospitals and the use of test medicines that comprise multiple ingredients which may 
vary in quality from batch to batch and may be affected by decoction conditions. These factors limit 
the comparability of studies. While there was no apparent publication bias based on the Funnel Plot 
for tRR, there may have been bias in favor of positive trials for other outcomes.  
How these HMs might work 
Except for Kang’ai injection, which was tested in two studies, different multi-herb decoctions or 
manufactured products were tested in each study. Therefore, on the basis of the clinical trial results 
alone, it is difficult to determine which individual herbs could have contributed to the reported effects. 
The main rationale for combining Chinese HMs with chemotherapy was the alleviation of AEs. Of the 
six most commonly used herbs in these RCTs, Astragalus, Ginseng, Atractylodes, Poria and Coix are 
traditionally used for fatigue, poor appetite, diarrhoea and other gastrointestinal disorders (Bensky et 
al., 2004) and each of these herbs has been reported to have immunomodulatory effects (Gong, 2010; 
Shergis et al., 2012; Yang et al., 2011). These actions may at least partially account for the reported 
improvements in AEs. In addition, recent experimental research into each of the six herbs used most 
frequently in the 13 studies indicates that each has effects that may contribute to the suppression of 
tumor growth. The findings of these studies are discussed below.  
Astragalus polysaccharides have been shown to have anti-proliferative effects in cell-line studies 
(Zong et al., 2012). Astragalus saponins inhibited proliferation in a human colorectal cancer HT-29 
cell line regardless of the p53 status, demonstrated tumor suppressive effects in a nude mice xenograft 
model, enhanced the cytotoxic effect of 5-FU (Tin et al., 2007) and have demonstrated anti-
angiogenic effects (Law et al., 2012). Astragalus flavonoids have also been reported to have pro-
apoptopic effects in colon cancer HCT-116 cells (Auyeung and Ko, 2010). 
A number of studies have found ginsenosides and ginseng polysaccharides to have anti-proliferative 
and pro-apoptopic effects (Nag et al., 2012; Zong et al., 2012). The ginsenoside Rg3 inhibited growth 
of tumours in-vivo in HCT-116 cells (He et al., 2011) and has shown anti-angiogenic activities (Wang 
et al., 2009b). Also, the ginseng saponin metabolite, compound K, has been reported to inhibit 
metastatic growth in hepatocellular carcinoma both in-vitro and in-vivo (Ming et al., 2011).  
Coix seed has a long history as an anti-cancer agent in China and has been developed into an 
injectable product (Kanglaite Coix oil extract) (Li, 2007; Woo et al., 2007). Coix extracts have been 
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shown to have anti-inflammatory and anti-carcinogenic effects in animal models of CRC (Chung et 
al., 2010; Li et al., 2011). Polysaccharides from Poria cocos appear to potentiate immune response by 
up-regulating immune stimulators and down-regulating immune suppressors and have shown 
antitumor activity in various cancer cell lines by suppressing tumor angiogenesis (Rios, 2011). 
 
Compounds derived from Atractylodes have shown bio-activity in-vitro. Anti-inflammatory effects 
have been reported for atractylenolide I and atractylenolide III (Li et al., 2007a) and atractylenolide II 
inhibited proliferation of B16 cells, induced G1 cell-cycle arrest and induced apoptosis (Ye et al., 
2011). In mouse splenocytes, Atractylodes glycoproteins stimulated both Th1 and Th2 lymphocyte 
proliferation with a greater effect on Th1 lymphocytes (Lee et al., 2007). In an RCT of cachetic 
cancer patients (n=64), the administration of a lactone from Atractylodes improved mid-arm muscle 
circumference, reduced the serum levels of interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-
alpha) and reduced urine proteolysis-inducing factors (PIF) (Liu et al., 2005).  
The alkaloids matrine and oxymatrine found in Sophora root have been developed into anti-cancer 
agents in China and Sophora flavonoids appear to have antitumor activity (Sun et al., 2012), for 
example, sophoflavescenol has shown cytotoxicity in a number of cancer cell lines as well as having 
antioxidant, anti-inflammatory and apoptotic activities (Jung et al., 2011).  
While it appears possible that at least some of the HMs used in these studies may have contributed to 
tumor response directly, it is also possible that this effect was indirect via alleviating AEs and thereby 
enabling patients to better tolerate the chemotherapy. Further research is needed to investigate these 
issues. 
 
Conclusion 
The meta-analysis results suggest the addition of these HMs to a FOLFOX4 regimen in ACRC increases 
tumor response rate (tRR) and one year survival but evidence is lacking for longer term effects. The addition 
of the HM interventions appear to have improved quality of life and reduced the incidence of severe 
neutropenia, nausea, vomiting, and neurotoxicity associated with the chemotherapy. Experimental studies on 
the actions of the most commonly used herbs suggest possible anti-tumor activity which may at least 
partially explain these results. However, methodological weaknesses were evident in each of the RCTs so 
any conclusions must be tentative. Further investigation is required using sufficiently powered, rigorously 
designed RCTs over longer durations. 
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Figure Titles and Legends 
 
Fig 1. Flow diagram of the search and selection process of RCTs of FOLFOX4 combined with herbal 
medicine (HM) for advanced colorectal cancer (ACRC) 
 
Fig 2. Funnel Plot of the 12 studies that reported tumor response rate (tRR) 
Label for X axis:  Risk Ratio (RR) for tumor response rate (tRR) 
Label for Y axis:  Sample size of study
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Table 1 Characteristics of the thirteen studies included in the analysis 
First author 
(year); 
Sample 
size T/C; 
Duration; 
Funding. 
 
Gender (M) 
T/C; 
Age T/C;  
KPS all. 
 
Previously 
untreated 
T/C; 
Previously 
treated 
T/C; 
Metastatic 
sites T/C. 
 
HM: name (manufacturer), ingredients 
(pinyin, scientific name, part); dosage & 
administration; 
FOLFOX4: cycles (T/C).  
Outcome measures HM AEs; 
Drop 
outs; 
Follow-
up. 
Risk of Bias  
(SG, AC, BPt, BOA, 
IOD, SOR) 
Ding X 
(2010); 
30/30;  
09/2007 to 
08/2008; 
NS. 
18/20; 
64.5/63; 
≥ 70. 
NS; 
NS; 
NS. 
Compound Kushen Injection (Zhendong Jinjing 
Pharmaceutical Co.): Ku shen, Sophora 
flavescens Ait. root; Bai tu ling, Heterosmilax 
yunnanensis Gagnep. root; 20 ml, ID, day 1-7, 
for 8 cycles; 
FOLFOX 4: 8/8. 
Median OS; 
Median TTP; 
AEs (leukopenia, 
nausea, vomiting, 
neurotoxicity); 
T-cell subsets (CD3+, 
CD4+, CD8+), NK 
cells. 
 
NS; 
None; 
20 
months: 
T: 4 lost 
to follow-
up C: 5 
lost to 
follow-up 
SG: L 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: U 
SOR: L 
 
Fang M 
(2008); 
48/45; 
05/2002 to 
06/2007; 
NS. 
30/28; 
59.5±11.3/56
.4±10.3; 
≥ 70.  
 
NS; 
NS; 
NS. 
 
Javanica oil Emulsion Injection (Shenyang 
Pharmaceutical University Pharmaceutical Co.): 
Yan dan zi, Brucea javanica (L.) Merr. seed; 30 
ml diluted with saline, 250 mL ID, day 1-14, for 
2 cycles; 
FOLFOX 4: 2/2. 
tRR; 
Chemotherapy AEs 
(leukopenia, anaemia, 
thrombocytopenia, 
nausea, vomiting, 
diarrhoea, stomatitis, 
neurotoxicity, alopecia); 
KPS. 
NS; 
None; 
NS. 
 
SG: L 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
 
Li HJ  
(2007); 
65/52; 
10/2002 to 
02/2006; 
NS. 
 
43/36; 
58/59 
(median); 
70(median). 
 
31/20; 
34/32; 
NS. 
 
Aidi Injection (Guizhou Yibai Pharmaceutical 
Co): Ren shen, Panax ginseng C.A.Mey. root; 
Huang qi, Astragalus membranaceus (Fisch.) 
Bge. Root; Ci wu jia, Acanthopanax senticosus 
(Ruper.et Maxim.) Harms. root; Ban mao, 
Mylabris phalerata Pallas; 60 ml (0.3g crude 
drug/ml) diluted with 250 ml 5% glucose 
tRR; 
Chemotherapy AEs 
(leukopenia, anaemia, 
thrombocytopenia, 
nausea, vomiting, 
diarrhoea, constipation, 
stomatitis, liver/kidney 
NS; 
None; 
Until 
05/2007. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
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injection fluid ID, day 1-10, 14 days/cycle, for 
11 weeks;  
FOLFOX 4:5.5/5.5 (mean) 
impairment, 
neurotoxicity, alopecia); 
Median OS;  
One year OS;  
KPS. 
 
Li YJ  
(2007); 
20/18; 
01/2005 to 
04/2006; 
NS. 
 
22 (all); 
72.7 (median, 
all); 
≥ 60. 
 
28(all); 
10(all); 
NS. 
 
Wenshenjianpi decoction (NS): Rou cong rong, 
Cistanche deserticola Y. C. Ma. herb; Yin yang 
huo, Epimedium grandiflorum Mot. leaf; Gou ji, 
Lycium barbarum L. fruit; Dang shen, 
Codonopsis pilosula (Franch.) Nannf. root; 
Huang qi, Astragalus membranaceus (Fisch.) 
Bge. root; Bai zhu, Atractylodes macrocephala 
Koidz. root; Fu ling, Poria cocos (Schw) Wolf 
sclerotium; Yi yi ren, Coix lacryma-jobi L. seed; 
Yu jin, Curcuma wenyujin Y. H. Chen et C. 
Ling. rhizome; Shan zha, Crataegus pinnatifida 
Bge. fruit; Mai ya, Hordeum vulgare L. 
germinating seed; Ban zhi lian, Scutellaria 
barbata D. Don. herb; modified. 
One decoction per day orally administered 
concurrently with chemotherapy for median 10-
12 weeks;  
FOLOFOX 4: 6/5.5 cycles (median) 
tRR; 
Chemotherapy AEs 
(leukopenia, anaemia, 
thrombocytopenia, liver 
impairment, nausea, 
vomiting, diarrhoea 
neurotoxicity); 
KPS. 
NS; 
C: 1 no 
reason 
given; 
NS. 
SG: L 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: H 
SOR: L 
 
Qiu ZC  
(2011); 
22/21*; 
01/2005 to 
08/2009; 
NS. 
14/13; 
56.9/52.7 
(median); 
≥ 60. 
 
22/21; 
NO; 
NS. 
Kang'ai Injection (Jilin Changbaishan 
Pharmaceutical Co): Ku shen, Sophora 
flavescens Ait. root; Ren shen, Panax ginseng 
C.A.Mey. root; Huang qi, Astragalus 
membranaceus (Fisch.) Bge. root; 40ml of 
Kang’ai injection diluted with 250 ml 5% 
glucose injection fluid ID, day 1-10, 14 
days/cycle, for 4 cycles;  
FOLFOX 4: 4/4 cycles. 
tRR; 
Chemotherapy AEs 
(leukopenia, nausea & 
vomiting); 
KPS. 
NS; 
None; 
NS. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
 
Wu GL  
(2010); 
23/17; 
55.4 
NS; 
NS; 
Fupiyiwei decoction (NS): Shi hu, Dendrobium 
loddigesii Rolfe. stem; Cang zhu, Atractylodes 
tRR; 
Chemotherapy AEs 
NS;  
None; 
SG: L 
AC: U 
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33/25; 
10/2004 to 
05/2008; 
Provincial 
fund. 
±13.6/52.8 
±15.2 
(mean); 
≥ 60. 
 
NS. lancea (Thumb.) DC. root; Yi yi ren, Coix 
lacryma-jobi L. seed; Ban xia Pinellia ternata 
(Thunb.) Breit. tuber; Shan yao, Dioscorea 
opposita Thunb. rhizome; Fu ling, Poria cocos 
(Schw) Wolf. sclerotium; Dou kou, Alpinia 
katsumadai Hayata. seed; Jiao gu lan, 
Gynostemma pentaphyllum (Thunb.) Mak. herb; 
Bai shao, Paeonia lactiflora Pall. root; Huo 
xiang, Pogostemon cablin (Blanco) Benth. herb; 
One decoction per day oral-administered 
concurrently with chemotherapy for 24 weeks;  
FOLFOX 4:12/12 cycles 
(leukopenia, anaemia, 
thrombocytopenia, 
nausea, vomiting, 
diarrhoea neurotoxicity);  
KPS;  
T-cell subsets (CD3+, 
CD4+, CD8+), NK 
cells. 
NS. BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
 
Xu YX  
(2010);  
61/60; 
08/2004 to 
11/2008; 
NS. 
38/37; 
53/52 
(mean); 
≥ 70. 
 
NS; 
NS; 
NS. 
 
Jiangniling decoction (NS): Dang shen, 
Codonopsis pilosula (Franch.) Nannf. root; Bai 
zhu, Atractylodes macrocephala Koidz. root; Fu 
ling, Poria cocos (Schw) Wolf. sclerotium; Bai 
dou kou, Amomum cardamomum L. seed, Ban 
xia, Pinellia ternata (Thunb.) Breit. tuber; Sha 
ren, Amomum villosum Lour. seed; Xiang fu, 
Cyperus rotundus L. rhizome; Chen pi, Citrus 
reticulata Blanco. peel; Zhu ru, Phyllostachyl 
nigra (Lodd.). shaving; Sheng jiang, Zingiber 
officinale Rosc. rhizome; Yi yi ren, Coix 
lacryma-jobi L. seed; One decoction per day 
orally administered concurrently with 
chemotherapy for 22 weeks;  
FOLFOX 4: 11.1/7.8 cycles (mean). 
tRR;  
Chemotherapy AEs 
(nausea, vomiting, 
diarrhoea, anaemia, 
leukopenia, 
thrombocytopenia); 
TTP;  
KPS.  
 
NS; 
None; 
NS. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
 
Yang YF 
(2008); 
30/30; 
01/2007 to 
11/2007; 
NS. 
 
16/19; 
51.07±10.44/
51.33 
±10.95 
(mean); 
40.73±3.49/ 
40.90±2.44. 
 
9/7; 
21/23; 
NS. 
Kang'ai Injection (Jilin Changbaishan 
Pharmaceutical Co): Ku shen, Sophora 
flavescens Ait. root; Ren shen, Panax ginseng 
C.A.Mey. root; Huang qi, Astragalus 
membranaceus (Fisch.) Bge. root; 50ml of 
Kang’ai injection diluted with 250 ml 5% 
glucose injection fluid ID per day, day 1-20, 30 
days/course, for 2 courses; 
tRR; 
Chemotherapy AEs 
(leukopenia, anaemia, 
thrombocytopenia, liver 
impairment, nausea, 
vomiting, diarrhoea, 
neurotoxicity);  
QOL, BW. 
NS; 
None; 
NS. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
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FOLFOX 4: 4/4 cycles. 
Zeng DX 
(2009); 
35/32; 
02/2007 to 
12/2008; 
Provincial 
fund. 
16/19; 
50-70 
(range);  
≥ 70. 
 
67(all); 
NO; 
Liver: 
15/19, 
Lung: 8/7, 
Others: 9/9. 
Ginsenoside Rg3 capsules (Jilin Yatai 
Pharmaceutical Co): 2 capsules/day, 
administered concurrently with chemotherapy 
for 8 weeks. 
FOLFOX 4: 4X4 cycles 
tRR;  
Chemotherapy AEs 
(leukopenia, nausea, 
vomiting, diarrhoea, 
neurotoxicity);  
T cell subsets (CD3+, 
CD4+, CD8+, 
CD4+/CD8+). 
NS; 
None; 
NS. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
 
Zeng JQ 
(2008); 
30/30; 
NS; 
NS. 
 
19/18; 
48/60 
(median);  
≥ 60. 
 
NO; 
30/30; 
Liver: 14/7, 
Lung: 6/8, 
Others: 
15/12. 
Basic HM formula (NS): Huang qi, Astragalus 
membranaceus (Fisch.) Bge. root; Bai zhu 
Atractylodes macrocephala Koidz. root; Yi yi 
ren, Coix lacryma-jobi L. seed; Ban zhi lian, 
Scutellaria barbata D. Don. herb; Ku shen, 
Sophora flavescens Ait. root; Mu xiang, 
Aucklandia lappa Decne. root; Bai hua she she 
cao, Hedyotis diffusa Willd. herb; modified; One 
decoction per day orally administered 
concurrently with chemotherapy for 4 weeks. 
FOLFOX 4: 2/2 cycles. 
tRR;  
Chemotherapy AEs 
(leukopenia, 
gastrointestinal reaction, 
neurotoxicity);  
KPS. 
NS;  
None; 
NS. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
 
Zhang HT 
(2008); 
31/29; 
03/2003 to 
11/2006; 
NS. 
 
 
28/23; 
52.35/53.4 
(mean); 
≥ 60. 
 
NS; 
NS; 
NS. 
3 HM decoctions based on CM ‘Zheng’ 
differentiation (NS):  
1. Damp heat tenesmus decoction: Ku shen, 
Sophora flavescens Ait. root; Zhong jie feng, 
Sarcandra glabra (Thunb.) Nakai. herb; Yi yi 
ren, Coix lacryma-jobi L. seed; Huai hua, 
Sophora japonica L. flower-bud; Di yu, 
Sanguisorba officinalis L. root; Bai jiang cao, 
Patrina villosa Juss. herb; Jin yin hua, Lonicera 
japonica Thunb. flower; Mu mian hua, Bombax 
malabarica (DC.) Merr. flower; Bai hua she she 
cao, Hedyotis diffusa Willd. herb; Yin chen, 
Artemisia capillaris Thunb. herb; Hou po, 
Magnolia officinalis Rehd. et Wils. bark; Huang 
lian, Coptis chinensis Franch. root. 
tRR;  
Chemotherapy AEs 
(gastrointestinal 
reaction, myelotoxicity); 
KPS. 
NS; 
None; 
NS. 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: L 
SOR: L 
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2. Toxic stasis in colon decoction: Ku shen, 
Sophora flavescens Ait. root; Zhong jie feng, 
Sarcandra glabra (Thunb.) herb; Huai hua, 
Sophora japonica L. flower-bud; Di yu, 
Sanguisorba officinalis L. root; Bai jiang cao, 
Patrina villosa Juss. herb; Jin yin hua, Lonicera 
japonica Thunb. flower; Bai hua she she cao, 
Hedyotis diffusa Willd. herb; Yan dan zi, Brucea 
javanica (L.) Merr. seed; Da ji, Cirsium 
japonicum DC. herb; Qi ye yi zhi hua, Paris 
polyphylla Smith. root; Chi shao, Paeonia 
veitchii Lynch. root; E zhu, Curcumae 
phaeocaulis Val. rhizome;  
3. Spleen and kidney deficiency decoction: Dang 
shen, Codonopsis pilosula (Franch.) Nannf. root; 
Fu ling, Poria cocos (Schw) Wolf. sclerotium; 
Huang qi, Astragalus membranaceus (Fisch.) 
Bge. root; Ku shen, Sophora flavescens Ait. 
root; Zhong jie feng, Sarcandra glabra (Thunb.) 
Nakai. herb; Yi yi ren, Coix lacryma-jobi L. 
seed; Sha ren, Amomum villosum Lour. s ed, 
Lian zi, Nelumbo nucifera Gaertn. Seed; Bai 
zhu, Atractylodes macrocephala Koidz. root; He 
zi, Terminalia chebula Retz. seed; He shou wu, 
Polygonum multiflorum Thunb. root; Bai shao, 
Paeonia lactiflora Pall. root;  
One decoction per day orally administered 
concurrently with chemotherapy. Started one 
week before chemotherapy till one week after 
chemotherapy completed.  
FOLFOX 4: 4/4 cycles. 
Zhang Q 
(2010); 
60/60; 
02/2005 to 
35/33; 
56.2 (mean 
all); 
≥ 60. 
32/34; 
28/26; 
Liver: 
32/36, 
Guben Xiaoliu Capsule (Beijing Chinese 
Medicine Hospital, affiliated with Beijing 
Medical University): Dong chong xia cao, 
Cordyceps sinensis (Berk.) Sacc. ascocarp and 
tRR;  
Chemotherapy AEs 
(leukopenia, anaemia, 
thrombocytopenia, 
NS; 
None; 
Until 
SG: L 
AC: U 
BPt: H 
BOA (sub): H 
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10/2007; 
Provincial 
fund. 
 Lung: 
16/19, 
Others: 
51/39. 
dead larva; Ling zhi, Ganoderma lucidum 
(Leyss. ex Fr.) Karst. sporocarp; Yin yang huo, 
Epimedium grandiflorum Mot. leaf; Zhe bei mu, 
Fritillaria thunbergii Miq. bulb; Xi yang shen, 
Panax quinquefolium L. root; Yi yi ren, Coix 
lacryma-jobi L. seed; Shui zhi, Hirudo 
nipponica Whitman. whole leech; Quan xie, 
Buthus martensii Karsch. whole insect; Long 
kui, Solanum nigrum L. herb; 4 capsules each 
time, twice a day, orally administered 
concurrently with chemotherapy for 8 wks. 
FOLFOX 4: 4/4 cycles. 
nausea & vomiting, 
diarrhoea, 
neurotoxicity);  
KPS;  
T cell subsets 
CD4+/CD8+,  
NK cells. 
07/2008. BOA (obj): L 
IOD: L 
SOR: L 
 
Zhang Y 
(2010); 
21/20; 
01/2005 to 
12/2008; 
State fund. 
NS; 
NS; 
≥ 60. 
 
NS; 
NS; 
NS. 
Jianpi Jiedu decoction (NS): Huang qi, 
Astragalus membranaceus (Fisch.) Bge. root; 
Bai zhu, Atractylodes macrocephala Koidz. 
root; Ba yue zha, Akebia quinata (Thunb.) 
Decne. fruit; Shi jian chuan, Salvia chinensis 
Benth. herb; Ye pu tao teng, Vitis 
quinquangularis Rehder. vine and leaf; One 
decoction per day orally administered 
concurrently with chemotherapy, for 4 w eks. 
FOLFOX 4: 2/2 cycles 
tRR;  
Chemotherapy AEs 
(leukopenia, anaemia, 
thrombocytopenia, liver 
impairment, nausea & 
vomiting, 
neurotoxicity);  
TTP; One year OS; 
Median OS;  
KPS; BW. 
NS, 
C: 1 no 
reason; 
Until 
11/2009. 
 
SG: U 
AC: U 
BPt: H 
BOA (sub): H 
BOA (obj): L 
IOD: H 
SOR: L 
 
T: treatment group, C: control group, M: male, N: number, NS: not stated, ID: intravenous drip, tRR: Tumor Response Rate; BW: Body Weight; QOL: Quality of Life; TTP: 
Time to Progression; OS: Overall Survival; KPS: Karnofsky Performance Status; CM: Chinese medicine; HM: herbal medicine.  
* note error in method section which states 20 in control, whereas elsewhere the number is 21.  
 
Risk of Bias Categories 
SG: Sequence Generation, AC: Allocation Concealment, BPt: Blinding of Participants/Personnel, BOA (sub): Blinding of Outcome Assessment (subjective measures), BOA 
(obj): Blinding of Outcome Assessment (objective measures), IOD: Incomplete Outcome Data, SOR: Selective Outcome Reporting.  
Risk of Bias Judgements 
L: low risk, U: Unclear risk, H: High risk 
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Table 2: Results of meta-analyses for each outcome measure  
Outcomes No. studies* 
(participant 
No.) 
Meta-analysis results (between groups at end of 
treatment) 
Incidence % (n/N) or 
MD ± SD 
RD (%) 
Tumor response     
Tumour response rate (tRR) 12
2-13 
(880) RR 1.25, 95% CI 1.06-1.47, p=0.007, I²=0% FE T: 44.1% (201/456) 
C: 34.9% (148/424) 
9.2 
Complete remission (CR) 92-9,12 (718)  RR 1.94, 95% CI 0.89-4.25, p =0.10, I²=0% FE T: 5.1% (19/374) 
C: 2.3% (8/344) 
2.8 
tRR (previously treated patients) 23,10 (126) RR 1.41,95% CI 0.77-2.61, p =0.27, I²=0% FE T: 29.7% (19/64) 
C: 21.0% (13/62) 
8.7 
tRR (previously untreated 
patients) 
33,5,9 (161) RR 1.19, 95% CI 0.85-1.67, p =0.32, I²=0% FE T: 51.1% (45/88) 
C: 42.4% (31/73) 
8.7 
tRR (Kang'ai Injection subgroup) 25,8 (103) RR 1.07, 95% CI 0.71-1.61, p =0.76, I²=0% FE T: 48.1% (25/52) 
C: 45.1% (23/51) 
3.0 
Overall survival (OS)     
One year OS 3
3,12,13
 (279)
 
RR 1.51, 95% CI 1.19-1.90, p =0.0006, I²=0% FE T: 62.3% (91/146) 
C: 42.1% (56/133) 
20.2 
Quality of life (QoL)     
Karnofsky Performance Status 
(KPS) 
93-5,7,9-13 (669) RR 1.84, 95% CI 1.54-2.19, p <0.00001, I²=0% FE T: 60.9% (210/345) 
C: 32.1% (104/324) 
28.8 
Mean KPS (Wu 2010) 16 (58) MD 12.18,95% CI 7.96-16.40, p<0.00001  T: before 74.38±11.16, after 
73.94±6.35 
C: before 75.16±12.78, after 
61.76±9.23 
NA 
Su Ying’s QoL Questionnaire 
(Yang 2008) 
1
8
 (60) MD 4.10, 95% CI 2.36 to 5.84, p<0.00001 T: before 40.73±3.49; after 
42.30±3.88 
C: before 40.90±2.44; after 
38.20±2.91 
NA 
Body weight (BW) 38,9,13 (169) RR 1.88, 95% CI 1.14-3.08, p =0.01, I²=0% FE T: 38.4% (33/86) 
C: 19.5% (16/82) 
18.9 
Chemotherapy toxicity     
Neutropenia events (grade 3/4) 10
1-6,8,10,12,13
 RR 0.33, 95% CI 0.18-0.60, p=0.0003, I²=0% FE T: 3.9% (14/359) 8.7 
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(692)  C: 12.6% (42/333) 
Nausea & vomiting (grade 3/4) 9
1-8,13
 (633)  RR 0.34, 95% CI 0.18-0.66, p=0.001, I²=0% FE T: 3.0% (10/330);  
C: 12.5% (38/303) 
9.5 
Neurotoxicity (grade 3/4) 7
1-4,12,13
 (529)  RR 0.39, 95% CI 0.15-1.00, p =0.05, I²=0% FE T: 2.2% (6/277)  
C: 6.0% (15/252) 
3.8 
Diarrhoea (grade 3/4) 5
2,3,6,8,12
 (448) RR 0.39,95% CI 0.11-1.42, p =0.15, I²=0% FE T: 0.9% (2/236)  
C: 3.3% (7/212) 
2.4 
Anaemia (grade 3/4) 36,12,13 (220) RR 0.30, 95% CI 0.05-1.89, p =0.20, I²=0% FE T: 0% (0/114)  
C: 2.9% (3/105) 
2.9 
Thrombocytopenia (grade 3/4) 113 (42) RR 1.00, 95% CI 0.07-14.95, p =1.00 FE T: 4.8% (1/21)  
C: 5.0% (1/20) 
NA 
Stomatitis (grade 3/4) 22,3 (210) RR 0.43,95% CI 0.08-2.31, p =0.33, I²=0% FE T: 1.8% (2/113)  
C: 4.1% (4/97) 
2.3 
Constipation (grade 3/4) 13 (117) RR 0.40,95% CI 0.04-4.29, p =0.45 FE T: 1.5% (1/65)  
C: 3.8% (2/52) 
NA 
Myolesuppression (grade 3) 1
11
 (60)  RR 0.47,95% CI 0.04-4.89, p =0.53 FE T: 3.23% (1/31) 
C: 6.90% (2/29) 
NA 
Kang'ai Injection Subgroup     
Neutropenia events (grade 3/4) 25,8 (103) RR 0.19,95% CI 0.04-0.83, p =0.03, I²=0% FE T: 3.8% (2/52)  
C: 21.6% (11/51)  
17.8 
Nausea & vomiting (grade 3/4) 25,8 (103) RR 0.27,95% CI 0.08-0.89, p =0.03, I²=0% FE T: 5.8% (3/52) 
C: 21.6% (11/51) 
15.8 
Immune function     
CD3+ cells (%) 2
1,6
 (118) MD 4.70, 95% CI 2.27 to 7.13, p=0.0001, I²=37% FE NA NA 
CD4+ cells (%) 21,6 (118) MD 9.08, 95% CI 0.10 to 18.05, p=0.05, I²=95% RE NA NA 
CD8+ cells (%) 21,6 (118) MD -4.47, 95% CI -9.54 to 0.61, p=0.08, I²=87% RE NA NA 
Ratio CD4+/CD8+ 2
1,12
 (180) MD 0.28, 95% CI 0.14 to 0.43, p=0.0002, I²=13% FE NA NA 
NK cells (%) 31,6,12 (238) MD 4.03, 95% CI 0.51 to 7.55, p=0.02, I²=88% RE NA NA 
T: test group; C: control group; RR: risk ratio; N: total number of participants in group(s); n: number of events in group(s); I²: test of heterogeneity of meta-
analysis, over 50% represents substantial heterogeneity; MD: mean difference; SD standard deviation; RD: Risk difference; NA: not applicable; FE: Fixed 
Effect model; RE: Random Effect model. 
*Included studies: 1. Ding X 2010, 2. Fang M 2008, 3. Li H 2007, 4. Li Y 2007, 5. Qiu Z 2011, 6. Wu G 2010, 7. Xu Y 2010, 8. Yang F 2008, 9. Zeng D 
2009, 10. Zeng J 2008, 11. Zhang H 2008, 12. Zhang Q 2010a, 13. Zhang Y 2010b. 
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Fig 1. Flow diagram of the search and selection process of RCTs of FOLFOX4 combined 
with herbal medicine (HM) for advanced colorectal cancer (ACRC) 
 
CT: clinical trial of HM without randomisation; DU: duplicate publication; MT: multi-cancer CT; RE: review; 
Other: not a controlled trial, or not a CT of HM, or outcome is not efficacy. 
Records identified through English 
database searches 
(n=732) 
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Records identified through Chinese 
databases  
CNKI (n=878) & CQVIP (n=317) 
(n = 246  ) 
Records after duplicates removed 
(n=1487) 
Records after screening titles & 
abstracts 
(n=236) 
Excluded based on full 
text (n=168) 
[CT n=59, DU n=12, MT 
n=38, RE n=4, Other n=55] 
RCTs of HM for CRC 
(n=68) 
Not FOLFOX4 for 
advanced CRC 
(n=55) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n=13) 
Records identified through searches of 
reference lists and print journals (n=37) 
Not a clinical study of 
CRC in humans 
(n=1251) 
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Fig 2. Funnel Plot of the 12 studies that reported tumor response rate (tRR)  
192x171mm (152 x 114 DPI)  
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